Skip to main content
SpringerLink
Log in

Pulmonary Toxicity of Therapy

  • Chapter
  • First Online:
The MASCC Textbook of Cancer Supportive Care and Survivorship

  • 1225 Accesses

Abstract

The pulmonary toxicity induced by novel antineoplastic agents has not been well characterized because of the simultaneous or sequential use of drugs and of a multimodality therapeutic approach. Diagnosis is based on exclusion of other factors that can cause respiratory failure in cancer patients including pneumonia, cardiogenic pulmonary edema, diffuse alveolar hemorrhage, and lymphangitic carcinomatosis. These conditions are not easily differentiated based on clinical presentation and radiographic findings, not even on lung biopsy specimens. Nonspecific interstitial pneumonitis, bronchiolitis obliterans with organizing pneumonia, eosinophilic pneumonia, pulmonary fibrosis, and diffused alveolar damage are the most common pathological patterns, but they are nonspecific for anticancer therapy-induced pulmonary toxicity. Clinicians should be aware of potential pulmonary toxicity as a complication in the treatment of cancer and focus on its early detection or prediction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vahid B, Marik P (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133: 528–538.

    Article  PubMed  CAS  Google Scholar 

  2. Dimopoulou I, Efstathiou E, Samakovli A et al (2004) A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: Clinical, radiological and functional assessment. Ann Oncol 15: 1250–1255.

    Article  PubMed  CAS  Google Scholar 

  3. Charpidou AG, Gkiozos I, Tsimpoukis S et al (2009) Therapy-induced toxicity of the lungs: an overview. Anticancer Res 9(2): 631–639.

    Google Scholar 

  4. Reed JC (2006) Proapoptotic multidomain Bcl-2/Bax-family ­proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13: 1378–1386.

    Article  PubMed  CAS  Google Scholar 

  5. Charpidou A, Blatza D, Anagnostou E et al (2008) Review: EGFR mutations in non-small cell lung cancer clinical impications. In Vivo 22(4): 529–536.

    PubMed  CAS  Google Scholar 

  6. Madani I, De Ruyck K, Goeminne H et al (2007) Predicting risk of radiation induced lung injury. J Thorac Oncol 2(9): 864–874.

    Article  Google Scholar 

  7. Bradley JD, Graham MV, Winter KW (2005) Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol 61: 318–328.

    Article  Google Scholar 

  8. Meadors M, Floyd J, Perry MC (2006) Pulmonary toxicity of ­chemotherapy. Semin Oncol 33(1): 98–105.

    Article  PubMed  CAS  Google Scholar 

  9. Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120: 617–624.

    Article  PubMed  CAS  Google Scholar 

  10. Dimopoulou I, Bamias A, Lyberopoulos P et al (2006) Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372–379.

    Article  PubMed  CAS  Google Scholar 

  11. Syrigou E, Syrigos K, Saif MW (2008) Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 8(1): 56–62.

    Article  PubMed  CAS  Google Scholar 

  12. Alsamarai S, Charpidou AG, Matthay RA et al (2009) Pneumonitis related to docetaxel: case report and review of the literature. In vivo 23: 635–637.

    PubMed  Google Scholar 

  13. Semb KA, Aamdal S, Oian P (1998) Capillary leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16: 3426–3432.

    PubMed  CAS  Google Scholar 

  14. Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III study of cisplatin, etoposide and concurrent radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: Hoosier oncology Group and U.S Oncology. J Clin Oncol 26(35): 5755–5760.

    Article  PubMed  CAS  Google Scholar 

  15. Takahashi T, Higashi S, Nishiyama H et al (2006) Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol 36: 104–108.

    Article  PubMed  Google Scholar 

  16. Vander Els NJ and Miller V (1998) Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 114: 1779–1781.

    Article  PubMed  CAS  Google Scholar 

  17. Arrieta O, Gallardo-Rinco D, Villarreal-Garza C et al (2009) High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 4: 845–852.

    Article  PubMed  Google Scholar 

  18. Sohn JH, Mon VW, Lee CG et al (2007) Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer 109: 1845–1850.

    Article  PubMed  CAS  Google Scholar 

  19. O’Brien ME, Ciuleanu TE, Tsekov H et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with small-cell lung cancer. J Clin Oncol 24: 5441–5447.

    Article  PubMed  Google Scholar 

  20. Yague XH, Soy E, Merino BQ et al (2005) Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 7: 515–517.

    Article  PubMed  Google Scholar 

  21. Nagaria NC, Cogswell J, Choe JK et al (2005) Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 23: 2423–2424.

    Article  PubMed  Google Scholar 

  22. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall-cell lung cancer. J Clin Oncol 23: 5892–5899.

    Article  PubMed  CAS  Google Scholar 

  23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.

    Article  PubMed  CAS  Google Scholar 

  24. Ohnishi K, Sakai F, Kudoh S et al (2006) Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib. Leukemia 20: 1162–1164.

    Article  PubMed  CAS  Google Scholar 

  25. Socinski MA, Novello S, Sanchez JM et al (2006) Efficacy and safety of sunitinib in previously treated, advanced non small cell lung cancer: preliminary results of a multicenter phase II trial. J Clin Oncol 24(18 suppl): 364s (Abstract 7001).

    Google Scholar 

  26. Duran I, Siu LL, Oza AM et al (2006) Characterization of the lung toxicity of the cell cycle inhibitor temisirolimus. Eur J Cancer 42: 1875–1880.

    Article  PubMed  CAS  Google Scholar 

  27. Rothenburger M, Teerling E, Bruch C et al (2007) Calcinurin inhibitor-free immunosuppression using everolimus (certican) in maintenance heart transplant recipients: 6 months’follow-up. J Heart Lung Transplant 26: 250–257.

    Article  PubMed  Google Scholar 

  28. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.

    Article  PubMed  CAS  Google Scholar 

  29. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27: 1227–1234.

    Article  PubMed  CAS  Google Scholar 

  30. Chua W, Peters M, Loneragan R et al (2009) Cetuximab- associated pulmonary toxicity. Clin Colo Cancer 8: 118–120.

    Article  Google Scholar 

  31. Vahid B and Mehrotra A (2006) Trastuzumab (herceptin)-­associated lung injury. Respirology 11: 655–658.

    Article  PubMed  Google Scholar 

  32. Tripathy D, Slamon DJ, Cobleigh M et al (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22: 1063–1070.

    Article  PubMed  CAS  Google Scholar 

  33. Azoulay E, Attalah H, Harf A et al (2001) Granulocyte colony-stimulating factor on neutrophil-induced pulmonary toxicity: myth or reality? Chest 120: 1695–1701.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sotiria General Hospital, Oncology Unit, GPP, Athens School of Medicine, Athens, 11527, Greece

    Kostas K. Syrigos

Authors
  1. Andriani G. Charpidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kostas K. Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kostas K. Syrigos .

Editor information

Editors and Affiliations

  1. Clinical Professor, Cancer Coucil Australia, University of Sydney Medical School, Surry Hills, 2010, New South Wales, Australia

    Ian N. Olver

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Society for Imaging Informatics in Medicine

About this chapter

Cite this chapter

Charpidou, A.G., Syrigos, K.K. (2010). Pulmonary Toxicity of Therapy. In: Olver, I. (eds) The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1225-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1225-1_11

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-1224-4

  • Online ISBN: 978-1-4419-1225-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation